Login to Your Account



Amicus, GSK Extend Their Fabry Disease Collaboration

By Marie Powers
Staff Writer

Wednesday, August 8, 2012

Amicus Therapeutics Inc. strengthened ties with partner GlaxoSmithKline plc to develop and commercialize its lead compound, the chaperone migalastat HC1 (Amigal), in Fabry disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription